{
  "trial_id": "NCT01104870",
  "trial_group": "hypertension",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, weight, body mass index (BMI), right heart catheterization results, mean pulmonary arterial pressure (PAPm) during exercise, type of exercise-induced pulmonary hypertension (idiopathic, heritable, drug- or toxin-induced, associated with connective tissue diseases or HIV infection, due to ILD, due to sarcoidosis), pulmonary function test results (forced vital capacity (FVC), total lung capacity (TLC), forced expiratory volume/forced vital capacity (FEV/FVC) ratio), 6-minute walk distance (6MWD), use of conventional pulmonary hypertension therapy, use of PDE-5 inhibitors or ERA, sex, pregnancy status, ability to communicate and cooperate with study protocol, informed consent status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Baseline Six-Minute Walk Distance (6MWD)",
          "6-minute walk distance (6MWD)"
        ],
        [
          "Background PAH Therapy",
          "use of conventional pulmonary hypertension therapy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "PAH History",
        "World Health Organization (WHO) Functional Class"
      ],
      "remaining_candidate_features": [
        "weight",
        "body mass index (BMI)",
        "right heart catheterization results",
        "mean pulmonary arterial pressure (PAPm) during exercise",
        "type of exercise-induced pulmonary hypertension (idiopathic, heritable, drug- or toxin-induced, associated with connective tissue diseases or HIV infection, due to ILD, due to sarcoidosis)",
        "pulmonary function test results (forced vital capacity (FVC), total lung capacity (TLC), forced expiratory volume/forced vital capacity (FEV/FVC) ratio)",
        "use of PDE-5 inhibitors or ERA",
        "pregnancy status",
        "ability to communicate and cooperate with study protocol",
        "informed consent status"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Body Mass Index, Baseline Pulmonary Artery Pressure (PAPm), Baseline Forced Vital Capacity (FVC), Baseline Forced Expiratory Volume/Forced Vital Capacity (FEV/FVC) ratio, Baseline 6-Minute Walk Distance (6MWD), Baseline Pulmonary Function Tests, Baseline Pulmonary Capillary Wedge Pressure (PCWPm), Baseline Left Ventricular Ejection Fraction (LVEF), Baseline Creatinine, Baseline Liver Function Tests (AST, ALT), Baseline Hemoglobin, Baseline Systolic Blood Pressure, Baseline Diastolic Blood Pressure, Use of Conventional Pulmonary Hypertension Therapy, Use of PDE-5 Inhibitor or ERA,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Baseline Six-Minute Walk Distance (6MWD)",
          "Baseline 6-Minute Walk Distance (6MWD)"
        ],
        [
          "Background PAH Therapy",
          "Use of Conventional Pulmonary Hypertension Therapy"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Region of Enrollment",
        "PAH History",
        "World Health Organization (WHO) Functional Class"
      ],
      "remaining_candidate_features": [
        "Body Mass Index",
        "Baseline Pulmonary Artery Pressure (PAPm)",
        "Baseline Forced Vital Capacity (FVC)",
        "Baseline Forced Expiratory Volume/Forced Vital Capacity (FEV/FVC) ratio",
        "Baseline Pulmonary Function Tests",
        "Baseline Pulmonary Capillary Wedge Pressure (PCWPm)",
        "Baseline Left Ventricular Ejection Fraction (LVEF)",
        "Baseline Creatinine",
        "Baseline Liver Function Tests (AST, ALT)",
        "Baseline Hemoglobin",
        "Baseline Systolic Blood Pressure",
        "Baseline Diastolic Blood Pressure",
        "Use of PDE-5 Inhibitor or ERA"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Pulmonary Artery Pressure, Pulmonary Vascular Resistance, Cardiac Output, 6-Minute Walk Distance, Forced Vital Capacity, Total Lung Capacity, Forced Expiratory Volume, Pulmonary Function Tests.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Baseline Six-Minute Walk Distance (6MWD)",
          "6-Minute Walk Distance"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "PAH History",
        "Background PAH Therapy",
        "World Health Organization (WHO) Functional Class"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Pulmonary Artery Pressure",
        "Pulmonary Vascular Resistance",
        "Cardiac Output",
        "Forced Vital Capacity",
        "Total Lung Capacity",
        "Forced Expiratory Volume",
        "Pulmonary Function Tests."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, weight, body mass index (BMI), forced vital capacity (FVC), total lung capacity (TLC), forced expiratory volume/forced vital capacity (FEV/FVC) ratio, 6-minute walk distance (6MWD), mean pulmonary artery pressure (PAPm) at rest and during exercise, pulmonary function tests, use of conventional pulmonary hypertension therapy, use of approved PDE-5 inhibitor or ERA, serum creatinine, liver function tests (AST, ALT), hemoglobin, systolic and diastolic blood pressure.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Baseline Six-Minute Walk Distance (6MWD)",
          "6-minute walk distance (6MWD)"
        ],
        [
          "Background PAH Therapy",
          "use of conventional pulmonary hypertension therapy"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "PAH History",
        "World Health Organization (WHO) Functional Class"
      ],
      "remaining_candidate_features": [
        "weight",
        "body mass index (BMI)",
        "forced vital capacity (FVC)",
        "total lung capacity (TLC)",
        "forced expiratory volume/forced vital capacity (FEV/FVC) ratio",
        "mean pulmonary artery pressure (PAPm) at rest and during exercise",
        "pulmonary function tests",
        "use of approved PDE-5 inhibitor or ERA",
        "serum creatinine",
        "liver function tests (AST, ALT)",
        "hemoglobin",
        "systolic and diastolic blood pressure"
      ]
    }
  }
}